Stock NKGN NKGEN BIOTECH, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages NKGen Biotech, Inc.

Equities

NKGN

US65488A1016

Real-time Estimate Cboe BZX
Other stock markets
 20:37:25 03/06/2024 BST 		5-day change 1st Jan Change
1.565 USD -6.29% Intraday chart for NKGen Biotech, Inc. +17.61% -39.27%
05-23 NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology Annual Meeting CI
05-20 NKGen Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Other languages

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
NKGen Biotech To Present Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy in Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024
Spotlighting Unexplored Stocks in Focus: NKGN, INBS, BTBT, PRSO, MGOL
NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology Annual Meeting
NKGen Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Sector Update: Health Care Stocks Softer Late Afternoon
Top Midday Gainers
Sector Update: Health Care Stocks Ease Monday Afternoon
NKGen Biotech Cell Therapy Gets Clearance to Start Phase 2 Clinical Trial in Alzheimer's Disease; Shares Rise
NKGen Biotech’s SNK01 NK Cell Therapy Cleared to Start Phase 2 Clinical Trial in Alzheimer’s Disease
NKGen Biotech, Inc.?s SNK01 NK Cell Therapy Cleares to Start Phase 2 Clinical Trial in Alzheimer?s Disease
NKGen Biotech Announces Upcoming Presentation on Autologous NK Cell Therapy at the 5th International Cell & Gene Therapy China Summit & Exhibition
NKGen Biotech, Inc. announced that it has received $0.2 million in funding from Meteora Capital, LLC, Glazer Capital, LLC
NKGen Biotech Announces FDA Clearance of Investigational New Drug (IND) Application for SNK01 NK Cell Therapy in Parkinson’s Disease
Nkgen Biotech Announces FDA Clearance of Investigational New Drug Application for SNK01 NK Cell Therapy in Parkinson's Disease
NKGen Biotech, Inc. announced that it has received $0.55 million in funding from FirstFire Capital Management LLC, Meteora Capital, LLC, Glazer Capital, LLC, Meteora Strategic Capital, LLC, Sandia Investment Managment LP
NKGen Biotech Presents Updated NK Cell Therapy Data for Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit
NKGen Biotech Announces Upcoming Publication at the 2024 American Society of Clinical Oncology Annual Meeting
NKGen Biotech Announces Upcoming Publication at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
NKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer's and Parkinson's Drug Development Summit
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NKGN Stock
  4. News NKGen Biotech, Inc.
  5. Other languages
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW